We can’t show the full text here under this license.
Abstract
The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment raises questions about their efficacy influenced by infusion timing.
- Observational studies suggest that morning infusion of ICIs may enhance their effectiveness compared to evening infusion.
- Many patients do not respond to ICIs, which are also associated with high costs and potential toxicity.
- The time of day for ICI infusion could significantly modulate treatment outcomes, warranting further investigation.
- Current evidence is limited and necessitates confirmation through pragmatic randomized clinical trials.
- may be supported by biological mechanisms linked to the circadian regulation of the immune system.
Simplified